Precise virulence inactivation using a CRISPR-associated transposase for combating Enterobacteriaceae gut pathogens.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40681864.
- Also identified by DOI 10.1038/s41551-025-01453-1 and PMC identifier 12915489.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeted gene manipulation in a complex microbial community is an enabling technology for precise microbiome editing. Here we introduce BACTRINS, an in situ microbiome engineering platform designed for efficient and precise genomic insertion of a desired payload and simultaneous knockout of target genes. This system leverages conjugation-mediated delivery of CRISPR-associated transposases to achieve RNA-guided genomic integration, allowing precise insertion of a therapeutic payload while neutralizing pathogen virulence without causing cell death. When applied against an Enterobacteriaceae Shiga toxin-producing pathogen in the gut, this system delivers a CRISPR-associated transposase by bacterial conjugation for site-specific inactivation of the Shiga toxin gene and integration of a nanobody therapeutic payload to disrupt pathogen attachment. A single dose of this therapy results in high-efficiency Shiga gene inactivation and improved survival in a murine infection model of Shiga-producing pathogen. This work establishes a new type of live bacterial therapeutic capable of reducing gut infections by transforming toxigenic pathogens into commensal protectors.
Medical subject headings
- Transposases
- Enterobacteriaceae
- CRISPR-Cas Systems
- Gastrointestinal Microbiome
- Clustered Regularly Interspaced Short Palindromic Repeats
- Enterobacteriaceae Infections